ReviewTranslational lung cancer research2018
The epidemiology of lung cancer.
Review in Translational lung cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05863013 (Longitudinal Changes in the ADL-Glittre Test in Patients With Lung Cancer), which is not on this map. Cited by 353 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Changes in the ADL-Glittre Test in Patients With Lung Cancer: Pre- and Postoperative Analysis Using Rehabilitation in a Randomized Controlled Trial
Who cites it
353 citing papers in PubMed, 1 synthesis or guideline pooled it, 705 citations in OpenAlex.
- Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- Cognitive Behavioural Therapy Group Counselling for Nicotine Dependence in College Students: Behavioural and Resting-State EEG Microstate Evidence.Addiction biology · 2026Trial
- Association of individual and neighborhood socioeconomic status with outcomes of a smoking cessation intervention provided in the lung cancer screening setting.Preventive medicine · 2025Trial
- Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.Cancer immunology, immunotherapy : CII · 2022Trial
- Sex-based inequities in non-small cell lung cancer: gaps and opportunities across the care pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Medical Debt and Advanced Cancer Stage at Diagnosis.JAMA network open · 2026Article
- Article
- Global trends in e-cigarette regulatory compliance: A bibliometric analysis of policies and emerging challenges.Medicine · 2026Article
- First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- From COPD and asthma to lung cancer: potential candidate genes and their associated biological pathways for the incidence risk of lung cancer.Journal, genetic engineering & biotechnology · 2026Article
- Review
- Stage-dependent prognostic value of clinical and pathological T staging in resected lung adenocarcinoma: a multicenter cohort study.BMC cancer · 2026Observational
- Targeting lung cancer with tanshinones: Current mechanistic evidence and emerging opportunities (Review).Oncology reports · 2026Review
- Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.Acta dermato-venereologica · 2026Article
- Proteomic stratification reveals immune metabolic heterogeneity in lung adenocarcinoma.Discover oncology · 2026Article
- The evolving disease burden of lung cancer (2014-2023) in Qingdao, China: An observational trend study with projections.Medicine · 2026Observational
- The problem with one-size-fits-all medicine: Biological sex and the aging immune system.PLoS biology · 2026Article
- Article
- Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance.Discover oncology · 2026Review
293 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and mortality from lung cancer is decreasing in the US due to decades of public education and tobacco control policies, but are increasing elsewhere in the world related to the commencement of the tobacco epidemic in various countries and populations in the developing world. Individual cigarette smoking is by far the most common risk factor for lung carcinoma; other risks include passive smoke inhalation, residential radon, occupational exposures, infection and genetic susceptibility. The predominant disease burden currently falls on minority populations and socioeconomically disadvantaged people. In the US, the recent legalization of marijuana for recreational use in many states and the rapid growth of commercially available electronic nicotine delivery systems (ENDS) present challenges to public health for which little short term and no long term safety data is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.